Related Experiment Video

Updated: Apr 25, 2026

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

9.3K

Phosphodiesterase 4D inhibitors limit prostate cancer growth potential

Ginny L Powers1, Kimberly D P Hammer1, Maribella Domenech2

  • 1Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin.

Molecular Cancer Research : MCR
|August 24, 2014
PubMed
Abstract

Insights

Phosphodiesterase 4D (PDE4D) inhibitors, NVP-ABE171 and cilomilast, effectively reduce prostate cancer cell growth in vitro and in vivo. These findings highlight PDE4D inhibition as a promising therapeutic strategy for prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Phosphodiesterase 4D (PDE4D) is overexpressed in prostate cancer and promotes cell proliferation.
  • The therapeutic potential of PDE4D inhibition in prostate cancer remains largely unexamined.

Purpose of the Study:

  • To investigate the anti-prostate cancer effects of selective PDE4D inhibitors, NVP-ABE171 and cilomilast.
  • To explore the impact of PDE4D inhibition on critical signaling pathways in prostate cancer.

Main Methods:

  • In vitro and in vivo studies using prostate cancer models.
  • Administration of PDE4D inhibitors NVP-ABE171 and cilomilast.
  • Analysis of signaling pathways including sonic hedgehog (SHH), androgen receptor (AR), and MAPK.
  • Assessment of tumor weight and apoptosis in xenograft models.

Main Results:

  • Both PDE4D inhibitors significantly decreased prostate cancer cell growth in vitro.
  • Inhibition of PDE4D reduced signaling in SHH, AR, and MAPK pathways, with SHH pathway correlation to growth inhibition.
  • PDE4D inhibitors decreased prostate weight in wild-type mice and reduced xenograft tumor weight with increased apoptosis.

Conclusions:

  • Pharmacologic inhibition of PDE4D demonstrates significant therapeutic potential for prostate cancer.
  • Small-molecule PDE4D inhibitors represent a viable option for prostate cancer treatment.

More Related Videos

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

2.5K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

5.7K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
812
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
608
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K